A Retrospective study to analyse the treatment outcomes of patients with severe atopic dermatitis (AD) who were enrolled in the Early Access to Medicines Scheme (EAMS) for dupilumab First published 28/02/2019 Last updated 14/03/2024 EU PAS number:EUPAS28596 Study Finalised